JP2018509890A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018509890A5 JP2018509890A5 JP2017540262A JP2017540262A JP2018509890A5 JP 2018509890 A5 JP2018509890 A5 JP 2018509890A5 JP 2017540262 A JP2017540262 A JP 2017540262A JP 2017540262 A JP2017540262 A JP 2017540262A JP 2018509890 A5 JP2018509890 A5 JP 2018509890A5
- Authority
- JP
- Japan
- Prior art keywords
- δ133p53β
- isoform
- δ133p53γ
- pluripotent stem
- induced pluripotent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000001708 Protein Isoforms Human genes 0.000 claims 22
- 108010029485 Protein Isoforms Proteins 0.000 claims 22
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims 19
- 238000000034 method Methods 0.000 claims 11
- 210000001082 somatic cell Anatomy 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 230000032683 aging Effects 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 210000002950 fibroblast Anatomy 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 230000008672 reprogramming Effects 0.000 claims 2
- 210000000130 stem cell Anatomy 0.000 claims 2
- 230000002463 transducing effect Effects 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010010099 Combined immunodeficiency Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims 1
- 208000011345 Duchenne and Becker muscular dystrophy Diseases 0.000 claims 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims 1
- 208000015872 Gaucher disease Diseases 0.000 claims 1
- 208000028735 Gaucher disease type III Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 241001529936 Murinae Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 201000009628 adenosine deaminase deficiency Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000036556 autosomal recessive T cell-negative B cell-negative NK cell-negative due to adenosine deaminase deficiency severe combined immunodeficiency Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000002659 cell therapy Methods 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 229910003460 diamond Inorganic materials 0.000 claims 1
- 239000010432 diamond Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000002242 embryoid body Anatomy 0.000 claims 1
- 230000007717 exclusion Effects 0.000 claims 1
- 238000000684 flow cytometry Methods 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 238000003306 harvesting Methods 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 230000001177 retroviral effect Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 208000002491 severe combined immunodeficiency Diseases 0.000 claims 1
- 208000002320 spinal muscular atrophy Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15305145 | 2015-01-30 | ||
| EP15305145.3 | 2015-01-30 | ||
| PCT/EP2016/052085 WO2016120493A1 (en) | 2015-01-30 | 2016-02-01 | Reprogramming method for producing induced pluripotent stem cells (ipsc) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018509890A JP2018509890A (ja) | 2018-04-12 |
| JP2018509890A5 true JP2018509890A5 (https=) | 2019-03-14 |
Family
ID=52589314
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017540262A Pending JP2018509890A (ja) | 2015-01-30 | 2016-02-01 | 人工多能性幹細胞（ｉＰＳＣ）の生産を再プログラムする方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US10767165B2 (https=) |
| EP (1) | EP3250679B1 (https=) |
| JP (1) | JP2018509890A (https=) |
| WO (1) | WO2016120493A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3510146B1 (en) | 2016-09-12 | 2026-02-11 | President and Fellows of Harvard College | Transcription factors controlling differentiation of stem cells |
| CA3038721A1 (en) * | 2016-09-30 | 2018-04-05 | Mayo Foundation For Medical Education And Research | Viral vectors for nuclear reprogramming |
| WO2018204262A1 (en) * | 2017-05-01 | 2018-11-08 | President And Fellows Of Harvard College | Transcription factors controlling differentiation of stem cells |
| GB2564437B (en) | 2017-07-10 | 2020-11-04 | Univ Brunel | Method of testing a gene therapy vector using induced pluripotent stem cells |
| EP3717654A4 (en) | 2017-12-01 | 2021-11-10 | President And Fellows Of Harvard College | METHODS AND COMPOSITIONS FOR PRODUCING OLIGODENDROCYTE PRECURSOR CELLS |
| US11788131B2 (en) | 2018-04-06 | 2023-10-17 | President And Fellows Of Harvard College | Methods of identifying combinations of transcription factors |
| AU2020282758A1 (en) * | 2019-05-30 | 2021-12-23 | Immunolux International Corp. | Use of poxvirus with autologous induced pluripotent stem cells for vaccination and disease therapy |
| KR20220027089A (ko) | 2019-05-31 | 2022-03-07 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | Sox9-유도된 핍지교세포 전구 세포 |
| GB201909975D0 (en) * | 2019-07-11 | 2019-08-28 | Babraham Inst | Novel reprogramming method |
| US20220273591A1 (en) * | 2019-07-26 | 2022-09-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for determining risk of developing insulin resistance |
| CN114736872A (zh) * | 2022-05-06 | 2022-07-12 | 中国科学院动物研究所 | 提高多能干细胞性能的组合物、方法及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2010010165A (es) * | 2008-03-17 | 2010-11-25 | Scripps Research Inst | Procedimientos quimicos y geneticos combinados para generacion de celulas madre pluripotentes inducidas. |
| CA2695590C (en) * | 2008-06-27 | 2018-01-09 | Kyoto University | Method of efficiently establishing induced pluripotent stem cells |
| WO2010033991A2 (en) * | 2008-09-22 | 2010-03-25 | Children's Medical Center Corporation | Detection of human somatic cell reprogramming |
| EP2272979A1 (en) * | 2009-06-30 | 2011-01-12 | Centre National de la Recherche Scientifique (CNRS) | Method for testing a subject thought to be predisposed to having cancer |
| CA2770412C (en) * | 2009-08-07 | 2018-09-11 | Kyoto University | Method of efficiently establishing induced pluripotent stem cells |
| AU2011308567B2 (en) * | 2010-10-01 | 2015-09-03 | Fundacion Centro Nacional De Investigaciones Oncologicas, Carlos Iii | Manipulation of stem cell function by p53 isoforms |
| WO2016120495A1 (en) * | 2015-01-30 | 2016-08-04 | Centre National De La Recherche Scientifique (Cnrs) | Delta133p53beta and delta133p53gamma isoforms are biomarkers of cancer stem cells |
-
2016
- 2016-02-01 US US15/547,212 patent/US10767165B2/en active Active
- 2016-02-01 EP EP16702146.8A patent/EP3250679B1/en active Active
- 2016-02-01 JP JP2017540262A patent/JP2018509890A/ja active Pending
- 2016-02-01 WO PCT/EP2016/052085 patent/WO2016120493A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018509890A5 (https=) | ||
| US20220143084A1 (en) | Modified natural killer (nk) cells for immunotherapy | |
| FI3599251T3 (fi) | Cd20-antigeeniin kohdentuvan kimeerisen antigeenireseptorin rakentaminen ja sillä muunnettujen t-solujen aktiivisuuden tunnistaminen | |
| TWI614340B (zh) | 體幹細胞及其製備方法 | |
| JP7449648B2 (ja) | リプログラミング前駆体組成物およびその使用方法 | |
| Yong et al. | Biosafety and bioefficacy assessment of human mesenchymal stem cells: what do we know so far? | |
| JP2019504644A (ja) | Ｔｒａｉｌとｃｄを発現している間葉系幹細胞およびその使用 | |
| Islam et al. | CCR6 functions as a new coreceptor for limited primary human and simian immunodeficiency viruses | |
| JP6143265B2 (ja) | 人工多能性幹細胞の選別方法 | |
| Kim et al. | Stem cells with fused gene expression of cytosine deaminase and interferon-β migrate to human gastric cancer cells and result in synergistic growth inhibition for potential therapeutic use | |
| Inada et al. | piggy Bac transposon-based immortalization of human deciduous tooth dental pulp cells with multipotency and non-tumorigenic potential | |
| TW202140779A (zh) | 唾液酸酶至癌細胞、免疫細胞及腫瘤微環境之輸送 | |
| Chen et al. | miR-19a/19b improves the therapeutic potential of mesenchymal stem cells in a mouse model of myocardial infarction | |
| JP2013530965A5 (https=) | ||
| CN104745551A (zh) | 利用talen敲除人乳头瘤病毒e6e7癌基因的方法 | |
| CN104726496B (zh) | 携带人类成年早衰症基因突变的多能干细胞及制备方法 | |
| Jahangiri et al. | Interleukin-12 inhibits tumor growth and metastasis promoted by tumor-associated mesenchymal stem cells in triple-negative breast cancer | |
| JP7798762B2 (ja) | Ｈｉｖ感染症を治療するための長寿命ｔ細胞 | |
| WO2004029301A3 (en) | Method for assaying replication of hbv and testing susceptibility to drugs | |
| Lu et al. | Multiplexed transcriptomic profiling of the fate of human CAR T cells in vivo via genetic barcoding with shielded small nucleotides | |
| Tang et al. | NKG2D-CAR-targeted iPSC-derived MSCs efficiently target solid tumors expressing NKG2D ligand | |
| CN104711240B (zh) | 禽呼肠孤病毒σA蛋白及其相关生物材料的应用 | |
| CN104762274B (zh) | 禽呼肠孤病毒σNS蛋白及其相关生物材料的应用 | |
| Qian et al. | Lentivirus‐modified human umbilical cord mesenchymal stem cells maintain their pluripotency | |
| Canjuga et al. | Homing of mRNA-modified endothelial progenitor cells to inflamed endothelium |